Narrow-moat CSL reiterated fiscal 2025 guidance for constant-currency group net profit after tax before amortization, or NPATA, of USD 3.2 billion to USD 3.3 billion, implying 10%-13% growth on fiscal ...
Narrow-moat CSL reiterated fiscal 2024 guidance for constant-currency group net profit after tax before amortization of USD 2.9 billion to USD 3.0 billion, implying 13%-17% growth on fiscal 2023. The ...
Stockhead on MSN
Dr Boreham’s Crucible: CSL’s tough diagnosis
A weak result and a sudden CEO departure have left CSL shares at eight-year lows. Management says the recovery plan ... Read ...
The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more ...
The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...
Both stocks have been hammered, but brokers see upside of 60% or more. The post Should you buy CSL and Pro Medicus shares today? appeared first on The Motley Fool Australia.
CSL shares slump to levels last seen in December 2017. The post Why the CSL share price just hit a 9-year low appeared first ...
I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine ("Seqirus") and plasma therapy ("Behring") segments. Seqirus is witnessing revenue declines as a result of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results